Cytosorbents Gains 10% Following Encouraging Top Line Results

Shares of Cytosorbents Corp (NASDAQ: CTSO) gained more than 10 percent on Friday after the company presented data from its first CytoSorb investigator-initiated septic shock study at an industry conference in Germany.

According to the company's press release, "All patients had refractory septic shock despite high doses of vasopressors, respiratory failure requiring artificial ventilation or extracorporeal membrane oxygenation (ECMO), anuric (no urine production) kidney failure requiring dialysis, and a significantly elevated initial mean lactate level of 8 mmol/L, indicating extreme metabolic and physiologic derangement. In these patients, all intensive care therapeutic options had been exhausted. Patients underwent consecutive twelve-hour extracorporeal CytoSorb treatments over several days, using a new CytoSorb cartridge for each treatment."

Preliminary key findings include a 28-day-survival rate of 41 percent, an approximate 30 to 40 percent absolute improvement in survival compared to an expected 0 to 10 percent survival rate. In addition, resolution of shock was achieved in 68 percent of [patients with CytoSorb therapy which translated into an improvement in clinical outcomes.

Dr. Axel Nierhaus, senior consultant at the Department for Intensive Care Medicine at University of Hamburg - Eppendorf, Germany, who chaired the symposium session, summarized the study as a "significant step to establish CytoSorb as a regular therapy for those moribund patients."